Clinical practice of renal cell carcinoma treatment with nivolumab

被引：0

作者：

Potocki, Pawel M. ^{[1
]}

Wysocki, Piotr J. ^{[1
]}

机构：

[1] Jagiellonian Univ, Coll Med, Dept Oncol, Krakow, Poland

来源：

ONCOLOGY IN CLINICAL PRACTICE | 2019年 / 15卷 / 05期

关键词：

kidney cancer; renal cell carcinoma; nivolumab; anti-PD-1; immunotherapy; checkpoint inhibitor; RANDOMIZED PHASE-3; CHECKMATE; 025; CANCER; EVEROLIMUS; IMMUNITY; SUNITINIB; BLOCKADE; EFFICACY; THERAPY; SAFETY;

D O I：

10.5603/OCP.2019.0002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Nivolumab alike other immune checkpoint inhibitors has been intensively developed during the last decade. Kidney cancer is among the neoplasm in treatment of which we have accumulated the most experience regarding nivolumab. As improves our understanding of the mechanisms underlying specific cellular immune response, thus improves our understanding of the place the nivolumab holds among other therapeutic options. Recent years brought development of innovative immunotherapy combinations as a method for improving immunotherapy efficacy. This review aims at providing practicing oncologists with key aspects of renal cell carcinoma treatment with nivolumab.

引用

页码：237 / 245

页数：9

共 50 条

[41] Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study [J].

Mollica, Veronica ;

Rizzo, Alessandro ;

Tassinari, Elisa ;

Giunchi, Francesca ;

Schiavina, Riccardo ;

Fiorentino, Michelangelo ;

Brunocilla, Eugenio ;

Ardizzoni, Andrea ;

Massari, Francesco .

ANTI-CANCER DRUGS, 2021, 32 (01) :74-81

[42] A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma [J].

Conduit, Ciara ;

Davis, Ian D. ;

Goh, Jeffrey C. ;

Kichenadasse, Ganessan ;

Gurney, Howard ;

Harris, Carole A. ;

Pook, David ;

Krieger, Laurence ;

Parnis, Francis ;

Underhill, Craig ;

Adams, Diana ;

Roncolato, Felicia ;

Joshua, Anthony ;

Ferguson, Tom ;

Prithviraj, Prashanth ;

Morris, Michelle ;

Harrison, Michelle ;

Begbie, Stephen ;

Hovey, Elizabeth ;

George, Mathew ;

Liow, Elizabeth C. ;

Link, Emma K. ;

McJannett, Margaret ;

Gedye, Craig .

BJU INTERNATIONAL, 2024, 133 :57-67

[43] Immunotherapy in renal cell carcinoma: A booming clinical research [J].

Baize, N. ;

Bigot, P. .

PROGRES EN UROLOGIE, 2018, 28 (03) :137-145

[44] Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab [J].

Ornstein, Moshe C. ;

George, Laeth ;

Wei, Wei ;

Diaz-Montero, C. Marcela ;

Rayman, Pat ;

Martin, Allison ;

Basu, Arnab ;

Beckermann, Kathryn E. ;

Nizam, Amanda ;

Wee, Christopher E. ;

Gilligan, Timothy D. ;

Gupta, Shilpa ;

Rini, Brian I. .

CLINICAL GENITOURINARY CANCER, 2024, 22 (06)

[45] Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma [J].

Zhang, Ying ;

Ettinger, Joerg ;

Ritter, Manuel ;

Schmidt-Wolf, Ingo G. H. .

CANCERS, 2020, 12 (09) :1-15

[46] Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation [J].

Bamias, Aristotle ;

Escudier, Bernard ;

Sternberg, Cora N. ;

Zagouri, Flora ;

Dellis, Athanasios ;

Djavan, Bob ;

Tzannis, Kimon ;

Kontovinis, Loukas ;

Stravodimos, Konstantinos ;

Papatsoris, Athanasios ;

Mitropoulos, Dionysios ;

Deliveliotis, Charalampos ;

Dimopoulos, Meletios-Athanasios ;

Constantinides, Constantine A. .

ONCOLOGIST, 2017, 22 (06) :667-679

[47] Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review [J].

Oki, Ryosuke ;

Takemura, Kosuke ;

Urasaki, Tetsuya ;

Fujiwara, Ryo ;

Numao, Noboru ;

Yonese, Junji ;

Miura, Yuji ;

Yuasa, Takeshi .

EXPERT REVIEW OF ANTICANCER THERAPY, 2025, 25 (06) :643-655

[48] Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma [J].

Sarfaty, Michal ;

Leshno, Moshe ;

Gordon, Noa ;

Moore, Assaf ;

Neiman, Victoria ;

Rosenbaum, Eli ;

Goldstein, Daniel A. .

EUROPEAN UROLOGY, 2018, 73 (04) :628-634

[49] Subcutaneous versus intravenous nivolumab for renal cell carcinoma [J].

Albiges, L. ;

Bourlon, M. T. ;

Chacon, M. ;

Cutuli, H. J. ;

Chuken, Y. A. L. ;

Zurawski, B. ;

Mota, J. M. ;

Magri, I. ;

Burotto, M. ;

Luz, M. ;

de Menezes, J. ;

Ruiz, E. P. Y. ;

Fu, S. ;

Richardet, M. ;

Valderrama, B. P. ;

Maruzzo, M. ;

Bracarda, S. ;

Breckenridge, M. ;

Vezina, H. E. ;

Rathod, D. ;

Yu, Z. ;

Zhao, Y. ;

Dixon, M. ;

Perumal, D. ;

George, S. .

ANNALS OF ONCOLOGY, 2025, 36 (01) :99-107

[50] Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma [J].

Choueiri, Toni K. ;

Fishman, Mayer N. ;

Escudier, Bernard ;

McDermott, David F. ;

Drake, Charles G. ;

Kluger, Harriet ;

Stadler, Walter M. ;

Perez-Gracia, Jose Luis ;

McNeel, Douglas G. ;

Curti, Brendan ;

Harrison, Michael R. ;

Plimack, Elizabeth R. ;

Appleman, Leonard ;

Fong, Lawrence ;

Albiges, Laurence ;

Cohen, Lewis ;

Young, Tina C. ;

Chasalow, Scott D. ;

Ross-Macdonald, Petra ;

Srivastava, Shivani ;

Jure-Kunkel, Maria ;

Kurland, John F. ;

Simon, Jason S. ;

Sznol, Mario .

CLINICAL CANCER RESEARCH, 2016, 22 (22) :5461-5471

← 1 2 3 4 5 →